ZA200408649B - Opthamological use of roflumilast for the treatment of diseases of the eye - Google Patents

Opthamological use of roflumilast for the treatment of diseases of the eye

Info

Publication number: ZA200408649B
Authority: ZA; South Africa
Prior art keywords: opthamological; roflumilast; diseases; eye; treatment
Prior art date: 2002-05-28

Application number

ZA200408649A

Other languages

English (en)

Inventor

Rudiger Koenen

Rudolf Linder

Original Assignee

Altana Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-28

Filing date

2004-10-26

Publication date

2007-12-27

2004-10-26 Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag

2007-12-27 Publication of ZA200408649B publication Critical patent/ZA200408649B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dispersion Chemistry (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ZA200408649A 2002-05-28 2004-10-26 Opthamological use of roflumilast for the treatment of diseases of the eye ZA200408649B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10223828		2002-05-28
EP02011830		2002-05-28
DE10311613		2003-03-14

Publications (1)

Publication Number	Publication Date
ZA200408649B true ZA200408649B (en)	2007-12-27

Family

ID=29587313

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ZA200408649A ZA200408649B (en)	2002-05-28	2004-10-26	Opthamological use of roflumilast for the treatment of diseases of the eye
ZA200409584A ZA200409584B (en)	2002-05-28	2004-11-26	Topically applicable pharmaceutical preparation

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ZA200409584A ZA200409584B (en)	2002-05-28	2004-11-26	Topically applicable pharmaceutical preparation

Country Status (32)

Country	Link
US (7)	US20060084685A1 (xx)
EP (3)	EP1511516B1 (xx)
JP (3)	JP5652983B2 (xx)
KR (2)	KR101307093B1 (xx)
CN (3)	CN101491520B (xx)
AT (2)	ATE485821T1 (xx)
AU (2)	AU2003232828B2 (xx)
BR (2)	BR0311337A (xx)
CA (2)	CA2486910C (xx)
CY (2)	CY1110312T1 (xx)
DE (2)	DE60334692D1 (xx)
DK (3)	DK1511516T3 (xx)
EA (2)	EA020569B1 (xx)
ES (3)	ES2354971T3 (xx)
HR (1)	HRP20041211B1 (xx)
HU (1)	HUE039709T2 (xx)
IL (3)	IL164935A (xx)
IS (1)	IS2639B (xx)
LT (1)	LT2020243T (xx)
MA (1)	MA27813A1 (xx)
ME (1)	ME00565A (xx)
MX (2)	MXPA04011612A (xx)
NO (2)	NO334882B1 (xx)
NZ (3)	NZ553731A (xx)
PL (3)	PL211870B1 (xx)
PT (3)	PT1511481E (xx)
RS (1)	RS51104B (xx)
SI (2)	SI2020243T1 (xx)
TR (1)	TR201815573T4 (xx)
UA (2)	UA81910C2 (xx)
WO (2)	WO2003099278A1 (xx)
ZA (2)	ZA200408649B (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872382B1 (en)	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
ATE485821T1 (de) *	2002-05-28	2010-11-15	Nycomed Gmbh	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
CN1684738A (zh)	2002-09-20	2005-10-19	爱尔康公司	细胞因子合成抑制剂用于治疗干眼病的用途
FR2851247B1 (fr)	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
PL1606261T3 (pl)	2003-03-10	2010-04-30	Astrazeneca Ab	Nowy sposób przygotowania roflumilastu
US20070082017A1 (en) *	2004-01-10	2007-04-12	Tseng Scheffer C	Lipid compositions and methods of use
DE102004046236A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
DE102004046235A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
JP5091106B2 (ja)	2005-03-08	2012-12-05	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	真性糖尿病の治療のためのロフルミラスト
WO2006097456A1 (en) *	2005-03-16	2006-09-21	Nycomed Gmbh	Taste masked dosage form containing roflumilast
WO2006132342A1 (ja) *	2005-06-09	2006-12-14	Santen Pharmaceutical Co., Ltd.	ロフルミラスト点眼液
WO2007097317A1 (ja)	2006-02-21	2007-08-30	Eisai R & D Management Co., Ltd.	４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体
EP2123641A4 (en)	2007-02-16	2011-06-22	Eisai R&D Man Co Ltd	CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT
EP2202229B1 (en)	2007-08-17	2012-03-14	Eisai R&D Management Co., Ltd.	Novel preparation for external use
CN101687820B (zh)	2007-08-17	2012-07-25	卫材R&D管理有限公司	喹唑啉衍生物的制造方法
MX2012004777A (es)	2009-10-30	2012-06-01	Nestec Sa	Metodos para mantener la salud de los ojos y mejorar enfermedades oftalmicas en caninos.
ES2377785B2 (es)	2010-09-08	2012-09-26	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento del ojo seco.
ES2408132B1 (es) *	2010-09-08	2014-04-04	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento de la epífora.
EP3320902B1 (en)	2011-03-07	2021-02-17	Amgen (Europe) GmbH	Methods for treating diseases using isoindoline compounds
CN102793684B (zh) *	2011-05-26	2016-02-17	杭州赛利药物研究所有限公司	罗氟司特液体制剂及其制备方法
AP2013007335A0 (en) *	2011-06-28	2013-12-31	Bayer Healthcare Llc	Topical ophthalmological pharmaceutical composition containing regorafenib
WO2013155123A1 (en) *	2012-04-10	2013-10-17	Georgia State University Research Foundation, Inc.	Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
CN103570610B (zh) *	2012-07-18	2017-08-11	重庆华邦制药有限公司	一种罗氟司特微粒的制备方法
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
CN111904962A (zh)	2012-11-08	2020-11-10	理森制药股份公司	含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物
TW201540301A (zh)	2013-08-16	2015-11-01	Takeda Gmbh	以ｐｄｅ４抑制劑治療認知損傷
CN105434328A (zh) *	2014-09-01	2016-03-30	天津药物研究院有限公司	一种含罗氟司特固体分散体的固体制剂及其制备方法
CN106573889B (zh) *	2014-10-24	2019-01-01	久光制药株式会社	前药
CN104997959A (zh) *	2015-08-21	2015-10-28	蔡宇平	一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) *	2016-07-11	2019-10-01	赵晨	一种遗传性Usher综合征的致病突变及其检测试剂
US12011437B1 (en)	2017-06-07	2024-06-18	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en)	2017-06-07	2018-02-20	Arcutis, Inc.	Inhibition of crystal growth of roflumilast
US12042487B2 (en)	2018-11-16	2024-07-23	Arcutis Biotherapeutics, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) *	2018-11-16	2020-05-21	Arcutis, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en)	2017-06-07	2021-09-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en)	2017-06-07	2021-06-03	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) *	2017-09-22	2022-12-27	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) *	2018-03-13	2018-07-17	兆科药业（广州）有限公司	一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
KR20210044191A (ko)	2018-06-04	2021-04-22	아큐티스, 인크.	로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
KR102117525B1 (ko) *	2018-07-09	2020-06-01	건양대학교 산학협력단	Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
CA3166300A1 (en) *	2020-01-31	2021-08-05	David W. Osborne	Topical roflumilast formulation having improved delivery and plasma half-life
US20230134782A1 (en) *	2020-05-07	2023-05-04	Arcutis Biotherapeutics, Inc.	Treatment of skin conditions using high krafft temperature anionic surfactants
MX2023006602A (es)	2020-12-04	2023-08-07	Arcutis Biotherapeutics Inc	Formulación tópica de roflumilast que tiene propiedades antimicoticas.
WO2022169615A1 (en)	2021-02-05	2022-08-11	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (zh) *	2021-02-10	2023-10-10	洛利克斯治疗有限公司	眼部递送罗氟司特的方法
IL304924A (en) *	2021-02-10	2023-10-01	Iolyx Therapeutics Inc	Methods for ophthalmic delivery of roflumilast
WO2022256412A2 (en) *	2021-06-01	2022-12-08	Eyedea Bio, Llc	Extended release drug delivery system for ocular drugs and methods of use
MX2024003580A (es)	2021-09-22	2024-04-05	Iolyx Therapeutics Inc	Metodos de tratamiento de enfermedades inflamatorias oculares.
US11850221B2 (en)	2021-12-17	2023-12-26	Aerie Pharmaceuticals, Inc.	Ophthalmic pharmaceutical compositions and uses thereof
IL313866A (en)	2021-12-28	2024-08-01	Arcutis Biotherapeutics Inc	Topical roflomilest spray foams
JP2025530005A (ja)	2022-09-15	2025-09-09	アーキュティス・バイオセラピューティクス・インコーポレーテッド	ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物
US20250082618A1 (en)	2023-09-07	2025-03-13	Arcutis Biotherapeutics, Inc.	Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) *	2023-09-15	2025-03-20	Arcutis Biotherapeutics, Inc.	Methods of reducing itch using topical roflumilast compositions
WO2025080415A1 (en)	2023-10-12	2025-04-17	Alto Neuroscience, Inc.	Treatment of neuropsychiatric disorders with tilivapram
CN117462487A (zh) *	2023-11-29	2024-01-30	沈阳药科大学	一种罗氟司特油凝胶及其制备方法
WO2025221488A1 (en)	2024-04-16	2025-10-23	Alto Neuroscience, Inc.	Transdermal administration of pde4 inhibitors for reduction in adverse events

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753945A (en) *	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) *	1988-05-31	1991-04-30	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) *	1992-09-14	1999-04-06	Wolf-Georg Forssmann	Use of inhibitors of phosphodiesterase IV
CA2165192C (en) *	1993-07-02	2001-04-24	Hermann Amschler	Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
CN1128955A (zh) *	1993-08-10	1996-08-14	藤泽药品工业株式会社	经皮吸收制剂
ZA954599B (en) *	1994-06-07	1996-01-26	Allergan Inc	Stable gel formulation for topical treatment of skin conditions
HK1042896A1 (zh) *	1998-09-29	2002-08-30	藤泽药品工业株式会社	吡啶并吡嗪化合物的新的盐及其结晶
US6395746B1 (en) *	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) *	1998-10-13	2002-01-17	John Kung	Composition to enhance permeation of topical skin agents
EP1161239B1 (en)	1999-03-10	2004-10-20	ALTANA Pharma AG	3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
KR20020050249A (ko) *	1999-10-29	2002-06-26	스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스	포스포디에스테라제 4 억제제의 투여 방법
ES2223772T3 (es) *	2000-01-31	2005-03-01	Pfizer Products Inc.	Pirimidincarboxamidas utiles como inhibidores de las isozimas pde4.
WO2001060358A1 (en) *	2000-02-16	2001-08-23	University Of Nebraska Medical Center	Method and compositions for treating fibrotic diseases
AU6196201A (en) *	2000-05-25	2001-12-03	Merck Frosst Canada Inc	Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
CA2427814C (en) *	2000-11-07	2009-06-02	Merck & Co., Inc.	A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) *	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) *	2001-11-09	2003-05-15	Johannes Barsig	Combination
ATE485821T1 (de) *	2002-05-28	2010-11-15	Nycomed Gmbh	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen

2003
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en not_active Ceased
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active Expired - Fee Related
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 EP EP03755048A patent/EP1511516B1/en not_active Expired - Lifetime
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Ceased
- 2003-05-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/en not_active Expired - Lifetime
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en not_active Ceased
- 2003-05-27 EP EP03730122A patent/EP1511481B1/en not_active Expired - Lifetime
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20050014844A (ko)	2005-02-07
DK1511516T3 (da)	2009-04-06
IS2639B (is)	2010-06-15
DK1511481T3 (da)	2011-01-24
DE60325354D1 (de)	2009-01-29
PT1511516E (pt)	2009-02-20
KR20110122230A (ko)	2011-11-09
HRP20041211B1 (hr)	2013-06-30
ES2319517T3 (es)	2009-05-08
NO334916B1 (no)	2014-07-14
BR0311337A (pt)	2005-03-15
PT2020243T (pt)	2018-11-09
SI1511516T1 (sl)	2009-06-30
RS51104B (sr)	2010-10-31
US20060084684A1 (en)	2006-04-20
ZA200409584B (en)	2006-05-31
EA200401517A1 (ru)	2005-06-30
US20190029956A1 (en)	2019-01-31
KR101307093B1 (ko)	2013-09-11
IL164935A (en)	2010-12-30
IL165065A0 (en)	2005-12-18
NZ553731A (en)	2007-07-27
US20080280958A1 (en)	2008-11-13
WO2003099334A1 (en)	2003-12-04
EP2020243A1 (en)	2009-02-04
US20110313005A1 (en)	2011-12-22
UA81910C2 (uk)	2008-02-25
IL164935A0 (en)	2005-12-18
NZ537308A (en)	2009-09-25
JP2012229245A (ja)	2012-11-22
IL209657A0 (en)	2011-02-28
IS7612A (is)	2004-12-23
JP2005529930A (ja)	2005-10-06
HK1079445A1 (zh)	2006-04-07
EP1511516B1 (en)	2008-12-17
EP2020243B1 (en)	2018-08-15
ATE417628T1 (de)	2009-01-15
PL212134B1 (pl)	2012-08-31
TR201815573T4 (tr)	2018-11-21
IL165065A (en)	2010-11-30
AU2003240719A1 (en)	2003-12-12
CA2486910A1 (en)	2003-12-04
NO334882B1 (no)	2014-06-30
RS101404A (sr)	2007-02-05
CN1655823B (zh)	2010-05-26
PL372095A1 (en)	2005-07-11
US20210116207A1 (en)	2021-04-22
EP1511481A1 (en)	2005-03-09
NO20045506L (no)	2004-12-16
JP2005529928A (ja)	2005-10-06
LT2020243T (lt)	2018-11-12
CY1110312T1 (el)	2015-01-14
CN1655782A (zh)	2005-08-17
EA010416B1 (ru)	2008-08-29
DE60334692D1 (de)	2010-12-09
CA2486910C (en)	2011-11-29
DK2020243T3 (en)	2018-11-19
PT1511481E (pt)	2011-01-14
UA88523C2 (ru)	2009-10-26
AU2003240719B2 (en)	2009-12-10
EA200702588A1 (ru)	2008-08-29
AU2003232828B2 (en)	2010-06-24
ES2354971T3 (es)	2011-03-21
CN1655823A (zh)	2005-08-17
EA020569B1 (ru)	2014-12-30
CN101491520B (zh)	2011-03-16
CA2486917C (en)	2011-11-22
PL397021A1 (pl)	2012-03-26
ME00565A (en)	2011-12-20
CY1121133T1 (el)	2019-12-11
SI2020243T1 (sl)	2018-11-30
CN100490804C (zh)	2009-05-27
AU2003232828A1 (en)	2003-12-12
BR0311339A (pt)	2005-03-22
JP5652983B2 (ja)	2015-01-14
US20060084685A1 (en)	2006-04-20
EP1511481B1 (en)	2010-10-27
EP1511516A1 (en)	2005-03-09
MXPA04011612A (es)	2005-03-07
MA27813A1 (fr)	2006-04-03
ES2693094T3 (es)	2018-12-07
US20140303215A1 (en)	2014-10-09
HUE039709T2 (hu)	2019-01-28
HRP20041211A2 (hr)	2006-04-30
WO2003099278A1 (en)	2003-12-04
CA2486917A1 (en)	2003-12-04
PL372082A1 (en)	2005-07-11
CN101491520A (zh)	2009-07-29
MXPA04011528A (es)	2005-02-14
NZ536920A (en)	2007-04-27
ATE485821T1 (de)	2010-11-15
PL211870B1 (pl)	2012-07-31
NO20045656L (no)	2004-12-27
JP5683538B2 (ja)	2015-03-11
HK1079437A1 (en)	2006-04-07

Publication	Publication Date	Title
ZA200408649B (en)	2007-12-27	Opthamological use of roflumilast for the treatment of diseases of the eye
ATE361077T1 (de)	2007-05-15	Indanylderivate zur behandlung von atemwegserkrankungen
NZ516347A (en)	2004-01-30	Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
WO2004045593A3 (en)	2004-08-12	Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP1663220A4 (en)	2007-04-18	PROCESS, SALTS, COMPOSITIONS AND USE
IL150817A0 (en)	2003-02-12	Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
NZ542305A (en)	2009-03-31	Treatment of proliferative diseases with an epothilone derivative and radiation
AU2002317182A1 (en)	2003-01-21	Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
AU2002238405A1 (en)	2002-10-03	Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases